Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine
Open accessThe DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
During the last decades, hiPSC-derived organoids have been extensively studied and used as in vitro models for several applications among which research studies. They can be considered as organ and tissue prototypes, especially for those difficult to obtain. Moreover, several diseases can be accurately modeled and studied. Hence, patient-derived organoids (PDOs) can be used to predict individual drug responses, thus paving the way toward personalized medicine. Lastly, by applying tissue engineering and 3D printing techniques, organoids could be used in the future to replace or regenerate damaged tissue. In this review, we will focus on hiPSC-derived 3D cultures and their ability to model human diseases with an in-depth analysis of gene editing applications, as well as tumor models. Furthermore, we will highlight the state-of-the-art of organoid facilities that around the world offer know-how and services. This is an increasing trend that shed the light on the need of bridging the publicand the private sector. Hence, in the context of drug discovery, Organoid Factories can offer biobanks of validated 3D organoid models that can be used in collaboration with pharmaceutical companies to speed up the drug screening process. Finally, we will discuss the limitations and the future development that will lead hiPSC-derived technology from bench to bedside, toward personalized medicine, such as maturity, organoid interconnections, costs, reproducibility and standardization, and ethics. hiPSC-derived organoid technology is now passing from a proof-of-principle to real applications in the clinic, also thanks to the applicability of techniques, such as CRISPR/Cas9 genome editing system, material engineering for the scaffolds, or microfluidic systems. The benefits will have a crucial role in the advance of both basic biological and translational research, particularly in the pharmacological field and drug development. In fact, in the near future, 3D organoids will guide the clinical decision-making process, having validated patient-specific drug screening platforms. This is particularly important in the context of rare genetic diseases or when testing cancer treatments that could in principle have severe side effects. Therefore, this technology has enabled the advancement of personalized medicine in a way never seen before.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 2×
“The latter is involved in embryonic development and has evident ethical problems that limit their applicability, while human iPSCs (hiPSCs) overcome this limitation as they are usually derived from a skin biopsy or other sources of adult cells and can be reprogrammed to be pluripotent stem cells, through the some repr…”
BackgroundSingle Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 1×
“, 2013), adult stem cells (ASCs) (Sato et al., 2009), or embryonic stem cells (ESCs) (Jo et al.”
BackgroundCerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · cited 3×
“reported the first protocol to generate cerebral organoids, which included interdependent brain regions, such as the cerebral cortex containing progenitor populations that produce mature cortical neuron subtypes (Lancaster et al., 2013).”
BackgroundReconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196 · cited 1×
“The derivation process of PSC organoids exploits both the ability of these stem cells to differentiate into several cell types and the organ development process, including spatial patterning and morphogenesis (Clevers 2016; Eiraku, M. et al., 2011; Lancaster et al., 2013).”
BackgroundBrain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure
Qian, X., Nguyen, H. N., Song, M. M., Hadiono, C., Ogden, S. C., Hammack, C., Yao, B., Hamersky, G. R., Jacob, F., Zhong, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.032 · Cited by 2,127
Self-organizing optic-cup morphogenesis in three-dimensional culture
Eiraku, M., Takata, N., Ishibashi, H., Kawada, M., Sakakura, E., Okuda, S., Sekiguchi, K., Adachi, T., & Sasai, Y. (2011) · Nature · doi:10.1038/nature09941 · Cited by 2,001
Cells of the adult human heart
Litviňuková, M., Talavera-López, C., Maatz, H., Reichart, D., Worth, C. L., Lindberg, E. L., Kanda, M., Polanski, K., Heinig, M., Lee, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2797-4 · Cited by 1,729 · cited 1×
“It has been recently reported that 11 cardiac cell types directly constitute the heart, such as atrial cardiomyocytes, ventricular cardiomyocytes, fibroblasts, endothelial cells, pericytes, smooth muscle cells, immune cells (myeloid and lymphoid), adipocytes, mesothelial cells and neuronal cells (Litviňuková et al., 2…”
BackgroundHuman primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · cited 1×
“Drug screening and discovery, being a scalable and robust technology, to study the efficacy and side effects of a large number of molecules simultaneously and with great precision (Broutier et al., 2017; Medle et al., 2022) 4.”
Background
Research works printed but not linked: 4
- Harford, 2022, RSV-induced changes in a 3-dimensional organoid model of human fetal lungs, PLoS One, 17, e0265094, 10.1371/journal.pone.0265094 · DOI
- 2022, Snyder institute for chronic diseases
- 2022, Karolinska institutet stem cell organoid
- Zhou, Patient-derived organoids in precision medicine: Drug screening, organoid-on-a-chip and living organoid biobank, Front. Oncol., 11, 5625, 10.3389/fonc.2021.762184 · DOI · Paper page
Cited by
Rahimi Darehbagh, R., Seyedoshohadaei, S. A., Ramezani, R., & Rezaei, N. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01987-1 · Cited by 167
“Combining stem cell therapy with other therapeutic approaches, such as Aβ immunization or small molecule inhibitors of Aβ and tau pathology, may provide synergistic benefits [78].”
BackgroundThe Promise and Potential of Brain Organoids
Smirnova, L., & Härtung, T. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302745 · Cited by 101
Zaver, S. A., Sarkar, M. K., Egolf, S., Zou, J., Tiwaa, A., Capell, B. C., Gudjonsson, J. E., & Simpson, C. L. (2023) · JCI Insight · doi:10.1172/jci.insight.170739 · Cited by 38
Sampaio, A. R., Maia, R., Ciardulli, M. C., Santos, H. A., & Sarmento, B. F. C. C. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102053 · Cited by 57
“Differences in genetic background, reprogramming efficiency, and differentiation protocols can lead to inconsistencies in cell behavior, tissue function, and experimental outcomes [173].”
Zhu, Z., Cheng, Y., Liu, X., Ding, W., Liu, J., Ling, Z., & Wu, L. (2025) · Cell Transplantation · doi:10.1177/09636897241303271 · Cited by 33
Advanced Cellular Models for Rare Disease Study: Exploring Neural, Muscle and Skeletal Organoids
Bombieri, C., Corsi, A., Trabetti, E., Ruggiero, A., Marchetto, G., Vattemi, G. N. A., Valenti, M. T., Zipeto, D., & Romanelli, M. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021014 · Cited by 24
“By studying cellular disease models, researchers may gain insights into how diseases develop, identify new molecular targets for specific therapies and test potential treatment approaches [1].”
BackgroundDecoene, I., Nasello, G., da Costa, R. M., Hall, G. N., Pastore, A., Hoven, I. V., Viseu, S. R., Verfaillie, C. M., Geris, L., Luyten, F. P., et al. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad091 · Cited by 19
Advances in the application of colorectal cancer organoids in precision medicine
Zhang, Y., Meng, R., Sha, D., Gao, H., Wang, S., Zhou, J., Wang, X., Li, F., Li, X., & Song, W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1506606 · Cited by 19
Preclinical Models of Neuroblastoma—Current Status and Perspectives
Krawczyk, E., & Kitlinska, J. B. (2023) · Cancers · doi:10.3390/cancers15133314 · Cited by 17
“This includes spheroids and organoids in various matrices, as well as more complex settings, such as microfluidic systems or material engineering for the scaffolds [33,143,144].”
BackgroundBiotechnological advances and applications of human pluripotent stem cell-derived heart models
Muniyandi, P., O’Hern, C., Popa, M. A., & Aguirre, A. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1214431 · Cited by 14
“Heart organoids have been used to explore the connections between metabolism and transcription regulation in protein kinase adenosine monophosphate-activated non-catalytic subunit gamma 2 (PRKAG2) cardiomyopathy caused by missense mutations in the PRKAG2 regulatory subunit (Ntusi et al., 2016; Manhas et al., 2022; Nov…”
MethodNa, D.-H., Cui, S., Fang, X., Lee, H., Eum, S. H., Shin, Y., Lim, S. W., Yang, C. W., & Chung, B. H. (2024) · Cells · doi:10.3390/cells13141190 · Cited by 16
“With the advancement of hiPSC-related research, there is active progress in the production of organoids mimicking various organs from hiPSCs [31–33].”
BackgroundSetsu, S., Morimoto, S., Nakamura, S., Ozawa, F., Utami, K. H., Nishiyama, A., Suzuki, N., Aoki, M., Takeshita, Y., Tomari, Y., et al. (2024) · Stem Cell Reports · doi:10.1016/j.stemcr.2024.11.007 · Cited by 15
Microfabricated sensors for non-invasive, real-time monitoring of organoids
Kim, Y., Chica, E., & Lee, H. J. (2024) · Micro and Nano Systems Letters · doi:10.1186/s40486-024-00216-y · Cited by 23
“Lastly, the pharmaceutical industry also benefits from this new model as organoids provide improved prediction of human responses to drugs, which reduces reliance on animal models and improves the efficiency of clinical trials [19].”
Mohamed, S. A. T., & Emin, N. (2023) · Biomedical Materials · doi:10.1088/1748-605x/ad12e2 · Cited by 8
Gurwitz, D., & Steeg, R. (2024) · Drug Development Research · doi:10.1002/ddr.22227 · Cited by 11
“Recently, organoid cultures are increasingly applied as tools for mimicking the three ‐ dimensional structure of human tissues and their interactions with other cell types, hormones, viruses, approved drugs, and drug candidate compounds (Hale et al., 2018; Novelli et al., 2023; Tebon et al., 2023).”
Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection
Azim, M. M. N., Bhajan, S. K., Park, J. H., Abass, K. S., Rahman, A., Choi, M., Choi, J., Park, S., Kim, H. J., Akter, S., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072954 · Cited by 8
Stem cell therapy: A promising therapeutic approach for skeletal muscle atrophy
Wang, Y., Chen, Z., Shen, Y., Wang, K., Han, Y.-M., Zhang, C., Yang, X.-M., & Chen, B. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i2.98693 · Cited by 8
“Compared to muscle cells or MSCs directly transplanted into patients, iPSCs are more abundant, can be easily isolated and purified using specific markers, and demonstrate robust differentiation capabilities[89-91].”
Randall‐Demllo, S., Al-Qadami, G. H., Raposo, A. E., Ma, C., Priebe, I. K., Hor, M., Singh, R., & Fung, K. Y. C. (2024) · Cancers · doi:10.3390/cancers16213664 · Cited by 6
“…derived from tissue biopsy can be more difficult to obtain and are limited in their ability to differentiate into non-organ specific cell types, they allow for more accurate modelling of tumour processes and provide an opportunity for personalised medicine and therapies to be explored [60,98].”
BackgroundMechanisms, Impact, and Therapeutic Strategies for Oxidative Stress in Metabolic Diseases
Reyed, R. M., & Prabhakar, P. K. (2025) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-7919-6.ch006 · Cited by 6
Inner Ear Organoids: A Hydrogel-Based Platform for Drug Screening and Deafness Modeling
Cao, Y., Liu, X., Chai, R., & He, Z. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01479-0 · Cited by 5
Revolutionising oral organoids with artificial intelligence.
Yang, J., Fischer, N. G., & Ye, Z. (2024) · PubMed Central · doi:10.12336/biomatertransl.2024.04.004 · Cited by 12
“24 While iPSCs are technically more complex, they can differentiate into nearly any lineage and better model organ development compared to ASCs, such as mesenchymal stem cells, which are widely studied for their immune-regulating properties.”
Gastric Cancer Treatment New Chapter: Organoid Models Leading Personalized Medicine
Meng, Y., Zhang, L., Yang, J., Wang, X., Zhu, M., & Kong, F. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00808-3 · Cited by 3
“The stem cells within organoids exhibit self-renewal capacity and unlimited proliferative potential, enabling rapid expansion within 1–2 weeks and facilitating large-scale drug library screening [9–11].”
Organoids in Genetic Disorders: from Disease Modeling to Translational Applications
Zhu, Y., Lin, N., Li, J., Zhang, H., Zhang, P., Cheng, X., Yang, Q., & Liu, L. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10973-x · Cited by 3
“The advent of organoid technology, fueled by break-throughs in induced pluripotent stem cells (iPSCs) since Yamanaka’s 2006 discovery [ 15 ], has redefined genetic dis - ease modeling [16].”
Xie, Z., Liu, M., Wang, S., Meng, T., Zou, H., Guan, Y., Song, Y., Kong, Y., Qin, L., Zhang, C., et al. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-11017-0 · Cited by 3
Ma, C., Koh, D., Nishimura, T., Takata, Y., Kameda, Y., Negoro, R., Ishiguro, N., Shibuta, M., Namatame, I., Tetsuka, K., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115887 · Cited by 3
Niemis, W., Peterson, S. R., Javier, C., Nguyen, A., Subiah, S., & Palmer, R. H. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292238 · Cited by 2
“Advancing therapies using patient-specific iPSCs, in turn, have emerged to the translation medicine; for instance, personalized treatments [24, 27, 28] and clinical trials [29, 30].”
BackgroundRETRACTED: Induced pluripotent stem cells: A game-changer in dentistry’s regenerative landscape
Ahmed, S., Seth, N., Goyal, R., Krishna, S., & Kale, P. P. (2024) · Journal of Cellular Biotechnology · doi:10.3233/jcb-240145 · Cited by 2
“Collaboration among these disciplines is essential for developing safe and effective regenerative strategies that translate from the laboratory to the clinic [18].”
RetractedLab-on-a-chip: A Stepping Stone for Personalized Healthcare Management
Kuru, C. İ., & Ulucan‐Karnak, F. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837673476-00221 · Cited by 2
Spitalieri, P., Lara, G., Michela, M., Cesare, S. D., Serena, M., Pecorari, R., Maria, N. A., Eleonora, C., Colasuonno, F., Gori, G., et al. (2024) · Aging · doi:10.18632/aging.206159 · Cited by 2
Self-citationSetsu, S., Morimoto, S., Nakamura, S., Ozawa, F., Tomari, Y., & Okano, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.18.537412 · Cited by 2
Conditionally Reprogrammed Cells as Preclinical Model for Rare Cancers
Krawczyk, E. (2025) · Cancers · doi:10.3390/cancers17172834 · Cited by 1
Organoids for Drug Repurposing: A Literature Review
Okuyama, R. (2025) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/8827167 · Cited by 1
“Organoids are typically produced in small batches, making it difcult to conduct large-scale experiments [26].”
Human airway organoids as a versatile model to study BSL-4 virus replication and pathogenesis
Wälzlein, J.-H., Reusch, S., Ospina-Garcia, J., Olmer, R., Schneider, M. A., Klotz, L. V., Klotz, C., & Kummer, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-45813-6 · Cited by 1
Casti, P., Brescia, M., Sala, L., Mencattini, A., Mastrangeli, M., van Meer, B. J., & Martinelli, E. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.118717 · Cited by 2
New Medicines Design, Development and Commercialization in the Era of AI
Nydén, M., & Bika, D. (2024) · Lecture notes in information systems and organisation · doi:10.1007/978-3-031-65782-5_10 · Cited by 2
Pillar/Perfusion Plates for Miniature Human Tissue Culture and Predictive Compound Screening
Kang, S. (2024) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc2332528
Considerations in the development of pluripotent stem cell–based therapies
Cunningham, J. J., Capela, A., Priest, C. A., & Brandon, E. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00004-3
Organoid-Based Models for Traumatic Brain Injury: Challenges, Innovations, and Future Perspectives
Gautam, M., & Agrawal, D. K. (2025) · Indian Journal of Neurotrauma · doi:10.1055/s-0045-1810106
“27 Researchers have effectively generated brain organoids that represent distinct areas of the brain, including the forebrain, midbrain, cerebellum, cortex, and hippocampus.”
Role of ncRNAs in Neurological Disorders and Cardiovascular Diseases
Sajid, M. I., Khan, F. A., Mohsin, H., Maqbool, M. B., Mahmood, F., Yaseen, M., Younas, M., Naziri, A., Haider, K. H., & Tiwari, R. K. (2026) · Experientia supplementum · doi:10.1007/978-3-032-06948-1_2
Advances in Stem Cell-Derived Organoids for Treating and Understanding Lung Diseases
Raut, N., Paliwal, H., Prajapati, B. G., Desai, S. A., & Patel, V. P. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00544-4 · Cited by 1
Kishore, A., Chauhan, S., & Bathala, M. (2026) · Research Square · doi:10.21203/rs.3.rs-9351966/v1
Komplexe 3D-Modelle als Schlüssel der Infektionsforschung
Neser, C., Wußmann, M., Lotz, C., Groeber-Becker, F., Steinke, M. R., Zdzieblo, D., & Popp, C. (2026) · BIOspektrum · doi:10.1007/s12268-026-2767-y
Zhou, X., Yan, X., Zhang, Z., Zhang, Z., Que, Y., Wang, Y., Zhang, Y., Lu, K., & Wang, L. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1890385
“CITE (Turhan et al., 2021; Novelli et al., 2022).”
Metadata
- Authors
- Novelli, G., Spitalieri, P., Murdocca, M., Centanini, E., & Sangiuolo, F.
- Affiliations
- University of Rome Tor Vergata (IT)
- University of Calabria (IT)
- Corresponding author
- Novelli, Giuseppe
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-09
- Volume
- 10
- Pages
- 1059579-1059579
- ISSN
- 2296-634X (ISSN-L)
- PMC
- PMC9869172
- OpenAlex
- W4313948710
- Cited by
- 43
- References
- 126
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 16 · 2023: 7
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- human induced pluripotent stem cells, organoids, patient-derived organoids, precision medicine, disease modeling, drug screening, personalized medicine, CRISPR/Cas9 genome editing, tumor models, organoid biobank, 3D organoid culture, tissue engineering, 3D printing, microfluidics, scaffolds, rare genetic disorders, drug repurposing, translational research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.